Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
19.01
+0.59 (3.20%)
At close: May 12, 2025, 4:00 PM
19.01
0.00 (0.00%)
After-hours: May 12, 2025, 4:00 PM EDT
Enliven Therapeutics Employees
Enliven Therapeutics had 62 employees as of December 31, 2024. The number of employees increased by 16 or 34.78% compared to the previous year.
Employees
62
Change (1Y)
16
Growth (1Y)
34.78%
Revenue / Employee
n/a
Profits / Employee
-$1,435,871
Market Cap
932.74M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62 | 16 | 34.78% |
| Dec 31, 2023 | 46 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ELVN News
- 5 weeks ago - Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting - PRNewsWire
- 2 months ago - Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - PRNewsWire
- 2 months ago - Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - PRNewsWire
- 4 months ago - Enliven's Early Data Stands Out From Peers - Seeking Alpha
- 6 months ago - Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PRNewsWire
- 6 months ago - Enliven Therapeutics to Present at the Jefferies London Healthcare Conference - PRNewsWire
- 8 months ago - Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia - GlobeNewsWire
- 8 months ago - Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML - GlobeNewsWire